ADDITION OF VOGLIBOSE TO THE DUAL COMBINATION THERAPY OF GLIMEPIRIDE AND METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES

Dr Bharat Gupta, Dr Girish Hiregaudar, Dr Kiran Patil, Dr Lakshman Jambgi, Dr Mahesh P

Abstract


Type 2 diabetic patients are often treated with a combination of antidiabetic agents. The need to use drugs with different and complementary mechanisms of action frequently arises in daily clinical practice. There are several reasons to do this; namely, the disease itself is progressive, with the deterioration of glycemic control over time, and monotherapeutic attempts to achieve and maintain glycemic control often fail in the long run1. Some patients do not accept insulin treatment because of the fear of needles and injections, the fear that the complications of diabetes

are caused by insulin, and other false beliefs, and are willing to take as many anti-diabetic pills. Several pharmacological agents have been developed to treat patients with type 2 diabetes mellitus. They either improve insulin resistance (biguanides and thiazolidinediones), stimulate insulin secretion from the β-cell (sulphonylureas and metaglinides), or decrease glucose absorption from the gut (α-glucosidase inhibitors)2. Metformin monotherapy is initially recommended along with lifestyle modifications (increased physical activity and weight loss) for glycemic management of type 2 DM. However, if glucose levels are not controlled in patients with type 2 diabetes, other classes of antidiabetic agents are then additionally required. Coadministration of glimepiride and metformin has been used to achieve glucose control3.


Keywords


VOGLIBOSE, GLIMEPIRIDE, METFORMIN, TYPE 2 DIABETES

Full Text:

PDF

References


Sharma AK, Srinivasan BP. Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Eur J Pharm Sci. 2009;38(5):433-444. doi:10.1016/j.ejps.2009.09.004

Derosa G, Putignano P, Bossi AC, et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol. 2011;666(1-3):251-256. doi:10.1016/j.ejphar.2011.05.051

Shin KH, Kim SE, Yoon SH, et al. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy korean male volunteers: A randomized. Clin Ther. 2011;33(11):1809-1818. doi:10.1016/j.clinthera.2011.10.003

Kim H soon, Kim D man, Cha B soo, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014;5(6):701-708. doi:10.1111/jdi.12201

González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009;23(6):376-379. doi:10.1016/j.jdiacomp.2008.09.002

Park CY, Kang JG, Chon S, et al. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. PLoS One. 2014;9(3). doi:10.1371/journal.pone.0087799

C. Rao AAF. Efficacy and safety of oral triple drug combination (voglibose, glimepiride and metformin) in the management of type 2 diabetes mellitus. Int J Curr Res Rev. 2013;5(16):20-26.

Ghadge AA, Kuvalekar AA. Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: Novel move towards combination therapies. Diabetes Metab Syndr Clin Res Rev. 2017;11:S5-S13. doi:10.1016/j.dsx.2016.08.009

Oh TJ, Yu JM, Min KW, et al. Efficacy and safety of voglibose plus metformin in patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Metab J. 2019;43(3):276-286. doi:10.4093/dmj.2018.0051

Faruqui AA. Safety and Efficacy of Fixed Dose Combination of Voglibose, Glimepiride and Metformin in Indian Type 2 Diabetes Mellitus Patients. Adv Diabetes Metab. 2016;4(3):49-54. doi:10.13189/adm.2016.040302


Refbacks

  • There are currently no refbacks.